Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | TXK | P42681 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | TGM1 | P22735 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31213431 | 1.00 | JAK3 (0.40) | JAK3BTKTXKKMT2AMEN1 | |
| SCHEMBL27089746 | 0.86 | KMT2A (0.52) | JAK3BTKTXKKMT2AMEN1 | |
| SCHEMBL20139704 | 0.83 | BTK (0.43) | JAK3BTKTXKKMT2AMEN1 | |
| SCHEMBL24467259 | 0.80 | MEN1 (0.38) | JAK3BTKTXKKMT2AMEN1 | |
| SCHEMBL20139012 | 0.79 | LMNA (0.48) | JAK3BTKTXKKMT2AMEN1 | |
| SCHEMBL20139289 | 0.77 | MEN1 (0.47) | JAK3BTKTXKKMT2AMEN1 | |
| SCHEMBL20143678 | 0.73 | BTK (0.56) | JAK3BTKTXKPOLBLMNA | |
| SCHEMBL16117954 | 0.71 | POLB (0.53) | KMT2AMEN1POLBTP53CFTR | |
| SCHEMBL16099091 | 0.71 | POLB (0.50) | KMT2AMEN1POLBTP53CFTR | |
| SCHEMBL30642264 | 0.71 | POLB (0.50) | KMT2AMEN1POLBTP53CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383884-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20220363676-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. | 2022-11-17 | — | — | US | disclosed |
| CN-110099684-B | Compounds and methods for modulating interleukin-2-inducible T cell kinase | 科尔沃斯制药股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-3534899-B1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3534899-B1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3534899-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | Corvus Pharmaceuticals, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| WO-2018089261-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089261-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | IL2, NFATC1, IL2RA | JAK3 341/4885BTK 398/4885TXK 201/4885 |
| US-20220363676-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | IL2, NFATC1, IL2RA | JAK3 341/4885BTK 398/4885TXK 201/4885 |
| US-20240383884-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | IL2, NFATC1, IL2RA | JAK3 341/4885BTK 398/4885TXK 201/4885 |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | IL2, NFATC1, IL2RA | JAK3 341/4885BTK 398/4885TXK 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.